title: Response.
authors.forename: Vikrant V
authors.initials: VV
authors.lastname: Sahasrabuddhe
authors.forename: Munira Z
authors.initials: MZ
authors.lastname: Gunja
authors.forename: Barry I
authors.initials: BI
authors.lastname: Graubard
authors.forename: Britton
authors.initials: B
authors.lastname: Trabert
authors.forename: Lauren M
authors.initials: LM
authors.lastname: Schwartz
authors.forename: Yikyung
authors.initials: Y
authors.lastname: Park
authors.forename: Albert R
authors.initials: AR
authors.lastname: Hollenbeck
authors.forename: Neal D
authors.initials: ND
authors.lastname: Freedman
authors.forename: Katherine A
authors.initials: KA
authors.lastname: McGlynn
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000453:epidemiology*; D008297:Male
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin